2012
Interstitial lung disease
Murray LA, Rubinowitz A, Herzog EL. Interstitial lung disease. Current Opinion In Rheumatology 2012, 24: 656-662. PMID: 22955020, DOI: 10.1097/bor.0b013e3283588de4.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisInterstitial lung diseaseSSc-ILDClinical presentationPulmonary fibrosisLung diseaseRecent clinical trialsConcepts of pathogenesisLymphocyte subsetsOrigin of fibroblastsEpithelial injuryLung fibrosisPathologic criteriaPredictive biomarkersPathogenic roleClinical trialsDisease progressionCell injuryPutative biomarkersDiseaseFibrosisDeadly diseaseCommon formMillions of peopleDevastating disease
2010
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype
Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation 2010, 90: 812-823. PMID: 20404807, PMCID: PMC3682419, DOI: 10.1038/labinvest.2010.73.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseSSc-ILD patientsSSc-ILDIL-10Normal controlsProfibrotic cellsSystemic sclerosisLung diseaseCollagen-producing cellsMCP-1Profibrotic phenotypeSSc-related interstitial lung diseaseFlow cytometryPeripheral blood profilesSSc-ILD cohortsIL-10 secretionSystemic sclerosis patientsExpression of CD163Blood of patientsHealthy aged controlsCultured CD14Profibrotic characteristicsProfibrotic mediatorsTNF levelsSclerosis patients